Cancer Moonshot Conference - Today 6/29/2016

I know I have said I am skeptical about this whole moonshot conference idea. Its only one day. And the idea of spending all that money on a one day conference doesn't do much for me. But the conference is today - June 29, 2016 so I am going to see what comes out of it.I went to their website and found that they are now trying to get people involved. They are asking for ideas. They provided sharing links and hashtags.They are working with CureClick to incorporate social media and get others involved. (If you do not follow along with CureClick to learn about clinical trials and their results, I suggest you do.)So my current thoughts are:I will see what comes out of the conference.I will try to follow along in the coming months. I will expect some big breakthroughs in the future.And will keep my mouth shut in the meantime.
Source: Caroline's Breast Cancer Blog - Category: Cancer & Oncology Tags: #CanServe #MoonshotSummit Source Type: blogs

Related Links:

      ·Application is being reviewed under FDA ’s Real-Time Oncology Review pilot programmeBasel, 27 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), for the treatment of people with unresectab le hepatocellular carcinoma (HCC) who have not received prior systemic therapy. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, wh...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
AbstractPurposeTo determine whether a red clover preparation plus dietary intervention administered to premenopausal women with breast cancer (BC), improves menopausal symptoms due to anti-oestrogen treatment, and hence promotes compliance with tamoxifen, prevents weight gain and is safe.MethodsSurgically-treated premenopausal women with oestrogen receptor (ER) positive disease taking tamoxifen were recruited to a prospective double-blind randomized trial (NCT03844685). The red clover group (N = 42) received one oral tablet/day (Promensil® Forte) containing 80  mg red clover extract for 24 month...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
AbstractAnastrozole is an aromatase inhibitor. Anastrozole competitively inhibits the aromatase enzyme, which synthesizes estrogen. It is used for estrogen receptor-positive breast cancers. A woman with breast cancer and anastrozole-induced dermatitis is described; the cutaneous side effects associated with aromatase inhibitors are also reviewed. Skin-related adverse events associated with aromatase inhibitor use are uncommon and may be delayed in appearance; the time of onset ranges from less than 5  days to 6 months (median 2 months). They present as either vasculitis, erythema nodosum, subacute cutaneous ...
Source: Dermatology and Therapy - Category: Dermatology Source Type: research
Pemphigus is a chronic autoimmune blistering disorder, characterized by (muco-)cutaneous erosions due to autoantibodies against desmoglein 3 and/or 1. Pemphigus induction might be associated with drugs, malignancy or radiation therapy (RT); the latter being only rarely described. A rigorous literature review revealed around 30 cases of RT-associated pemphigus, which had been primarily treated with topical and/or systemic steroids, in some cases also dapsone or few other immunosuppressive agents were given. The most common underlying cancer type was breast cancer. We here present a 63-year-old male patient, who was pre-trea...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
In this study, we assessed the impact of interacting medication and pharmacogenetic variation to better explain apixaban concentration differences among 358 Caucasian AF patients. Genotyping (ABCG2,ABCB1,CYP3A4*22,CYP3A5*3) was performed by TaqMan assays, and apixaban quantified by mass spectrometry. The typical patient was on average 77.2  years old, 85.5 kg, and had a serum creatinine of 103.1 µmol/L. Concomitant amiodarone, an antiarrhythmic agent and moderate CYP3A/ABCB1 inhibitor, the impaired-function variantABCG2 c.421C  >  A, and sex predicted higher apixaban concentrations whe...
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research
We present the results of a phase I study of an oral selective gamma secretase (GS) inhibitor (critical to Notch signaling), RO4929097 in combination with neoadjuvant chemotherapy for operable triple negative breast cancer. The primary objective was to determine the maximum tolerated dose (MTD) of RO4929097. Secondary objectives were to determine real-time pharmacokinetics of RO4929097 and paclitaxel, safety and pathologic (pCR) complete response to study treatment. Eligible patients, initiated carboplatin at AUC 6 administered intravenously (IV) on day 1, weekly paclitaxel at 80  mg/m2 IV and RO4929097 10 mg dai...
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
This study provides useful concepts in assessing the contribution of BCRP on intestinal absorption in drug discovery and development process.
Source: Pharmacology Research and Perspectives - Category: Drugs & Pharmacology Authors: Tags: ORIGINAL ARTICLE Source Type: research
In metastatic breast cancer, top news at SABCS 2019 focused on two highly active drugs in HER2+ disease, an oral paclitaxel in TNBC, and evidence for a new standard front-line therapy in HR+ disease.Medscape
Source: Medscape Today Headlines - Category: Consumer Health News Tags: None ReCAP Source Type: news
Abstract Dysregulation of calcium homeostasis is a major mechanism of doxorubicin (DOX)-induced cardiotoxicity. Treatment with DOX causes activation of sarcoplasmic reticulum (SR) ryanodine receptor (RYR) and rapid release of Ca2+ in the cytoplasm resulting in depression of myocardial function. The aim of this study was to examine the effect of dantrolene (DNT) a RYR blocker on both the cardiotoxicity and antitumor activity of DOX in a rat model of breast cancer. Female F344 rats with implanted MAT B III breast cancer cells were randomized to receive intraperitoneal DOX twice per week (12 mg/kg total dose), 5...
Source: Translational Oncology - Category: Cancer & Oncology Authors: Tags: Transl Oncol Source Type: research
Conflicting literature exists regarding the relationship of combined oral contraceptives (COCs) and breast cancer risk. Although earlier studies demonstrated an association between the use of COCs and overall breast cancer risk in previous and current users, more recent research exhibits a small increased risk in current users only, with risk declining within 5 years after discontinuation. Furthermore, recent research demonstrates that COCs may protect against ovarian, endometrial, and colorectal cancer.
Source: The Journal for Nurse Practitioners - Category: Nursing Authors: Tags: Featured Article Source Type: research
More News: Blogging | Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Conferences | Learning | Oral Cancer | Universities & Medical Training | Websites